Volume 27, Issue 3 (5-2020)
RJMS 2020, 27(3): 138-159 |
Back to browse issues page
Research code: ندارد
Ethics code: ندارد
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Sadeghinejad M, Saeidi M, Momen S, Saadatirad M T, Mohseni F. COVID-19 diagnosis, treatment, and management: Key features you need to know. RJMS 2020; 27 (3) :138-159
URL: http://rjms.iums.ac.ir/article-1-6136-en.html
URL: http://rjms.iums.ac.ir/article-1-6136-en.html
Tehran University of Medical Sciences, Tehran, Iran , labmsn9@gmail.com
Abstract: (4007 Views)
In December 2019, a new type of viral pneumonia emerged in Wuhan, Hubei Province, China. Subsequently, the World Health Organization (WHO) named this unknown virus as (2019-novel coronavirus) on January 12, 2020, and then designated as “SARS-CoV-2”. This novel disease has no comprehensive guidelines of treatment, diagnosis, control, and prevention. An evidence-based guideline needs to be developed forthwith for frontline physicians and other involved healthcare workers in the fight against COVID-19 pneumonia. Therefore, we prepared this guideline following WHO recommendation, clinical studies, and clinical data of different studies. At present, the RT-PCR technique is approved as a determined diagnostic method for COVID-19. In addition, CT scans and Chest-X-Rays play a prominent role in follow up treatment and recovery statues of disease, and applicable for early detection of COVID-19. Regarding the treatment, drugs such as Chloroquine, an anti-malarial drug, and Lopinavir/Ritonavir, an anti-HIV drug, have shown significant antiviral activity against COVID-19. Other candidate drugs such as approved nucleoside analogues (favipiravir and ribavirin) and experimental nucleoside analogues (Remdesivir and Galidesivir) may have potential antiviral activity against COVID-19. Further, Pegylated Interferon Alfa-2a/b, an approved drug for the treatment of HBV and HCV, can also be exerted to stimulate the intrinsic antiviral response in patients with covid-19. Eventually, we further discussed other potential therapeutic agents and diagnostic strategies for the treatment, detection, and evaluation of covid-19 pneumonia to assist the healthcare workers in clinical sections.
Type of Study: review article |
Subject:
Infectious Disease
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
